NCT01965626View on ClinicalTrials.gov

A Multicenter Randomized Open-label Study of Oseltamivir Combined With HD-DEX Versus HD-DEX in the Management of ITP

PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

February 1, 2016

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2019

Conditions
Thrombocytopenia
Interventions
DRUG

Oseltamivir

Oseltamivir 75 mg twice per day, 10 consecutive days

DRUG

Dexamethasone

HD-DXM (orally at 40 mg daily for 4d)

Trial Locations (1)

250012

Qilu hospital, Shandong University, Jinan

All Listed Sponsors
lead

Shandong University

OTHER

NCT01965626 - A Multicenter Randomized Open-label Study of Oseltamivir Combined With HD-DEX Versus HD-DEX in the Management of ITP | Biotech Hunter | Biotech Hunter